These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33285212)

  • 1. The Impact of Histopathological Features of Prostate Cancerous Lesions on Multiparametric Magnetic Resonance Imaging Findings using PI-RADS Version 2.
    Naito H; Kato T; Ishikawa R; Tanaka K; Ueda N; Matsuoka Y; Miyauchi Y; Taoka R; Tsunemori H; Haba R; Nishiyama Y; Sugimoto M; Kakehi Y
    Urology; 2021 Mar; 149():174-180. PubMed ID: 33285212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
    Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
    Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
    J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Pockros B; Stensland KD; Parries M; Frankenberger E; Canes D; Moinzadeh A
    Prostate; 2022 Feb; 82(3):352-358. PubMed ID: 34878175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
    Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
    Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.
    Brancato V; Aiello M; Basso L; Monti S; Palumbo L; Di Costanzo G; Salvatore M; Ragozzino A; Cavaliere C
    Sci Rep; 2021 Jan; 11(1):643. PubMed ID: 33436929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The visibility of prostate cancer concerning underlying histopathological variances: A single-center multiparametric magnetic resonance imaging study.
    Arslan A; Alis D; Tuna MB; Sağlıcan Y; Kural AR; Karaarslan E
    Eur J Radiol; 2021 Aug; 141():109791. PubMed ID: 34062471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
    J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.